Due to the fact permitted in 2014, tucidinostat was considered as a next-line and subsequent therapy for PTCL sufferers in China. Clinical trials and preclinical reports in several hematological malignancies and strong tumors is in development. In summary, even though the scientific result of tucidinostat with the therapy of PTCL https://tupenib196ngw6.webdesign96.com/profile